General Information of Drug (ID: DMLMU63)

Drug Name
A-443654 Drug Info
Synonyms A-4436554
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10172943
ChEBI ID
CHEBI:91351
CAS Number
CAS 552325-16-3
TTD Drug ID
DMLMU63

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Capivasertib DM9SKW8 Breast cancer 2C60-2C65 Approved [3]
Enzastaurin DM5H0R9 Diffuse large B-cell lymphoma 2A81 Phase 3 [3]
GDC-0068 DMWBZJD Breast cancer 2C60-2C65 Phase 3 [3]
CI-1033 DMSI8N3 Lymphoma 2A80-2A86 Phase 2 [4]
CMX-2043 DMPSCVY Cardiac disease BA00-BE2Z Phase 2 [5]
ARQ 092 DM5WK0J Proteus syndrome LD2C Phase 2 [6]
GSK2110183 DMZHB37 leukaemia 2A60-2B33 Phase 2 [7]
RX-0201 DMTBAV3 Pancreatic cancer 2C10 Phase 2 [8]
PTX-200 DM0ZIT2 Breast cancer 2C60-2C65 Phase 2 [3]
Triciribine prodrug DMBN1XS Solid tumour/cancer 2A00-2F9Z Phase 1/2 [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
RAC-alpha serine/threonine-protein kinase (AKT1) TTWTSCV AKT1_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8204).
2 Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension. J Med Chem. 2007 Jun 28;50(13):2990-3003.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
5 Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
8 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.